IVD China last week: Thermo Fisher Scientific and Health Gene, Merck and Abbisko Therapeutics, Snibe, Hipro Biotechoiogy and Qlife, Wondfo

Thermo Fisher Scientific China visited Health Gene Technologies

Recently, Gene Science Division Team of Thermo Fisher Scientific China visited Health Gene Technologies.

China's IVD industry has entered a period of rapid development, and new technologies continue to emerge to challenge the industry. In the face of increasingly fierce competition in the market environment, Health Gene Technologies and Thermo Fisher Scientific discussed the direction of strategic cooperation in the future, hoping to use innovative technology to enable industrial upgrading, enhance brand influence, and accelerate market development. At the same time, jointly promote the application and development of the CE platform in the field of precision medicine and scientific research, provide customers with more quality products and services, and write a new chapter of win-win cooperation.

Merck struck a deal with Abbisko Therapeutics

On December 4, Merck announced a licensing agreement with Shanghai Abbisko Therapeutics for Pimicotinib (ABSK021). Pimicotinib is currently being evaluated in a Phase III clinical trial for giant cell tumor of tendon sheath (TGCT). Giant cell tumor of tendon sheath is a benign tumor of the joint that causes swelling, pain, stiffness, and limited movement of the joint. The disease can seriously affect patients' quality of life, and treatment options are currently very limited. 

Under the terms of the agreement, Abbisko will receive a one-time, non-refundable down payment of $70 million and an additional exercise fee if Merck exercises a global commercialization option. With the addition of R&D milestone payments and sales milestone payments, the total potential payment could be as high as $605.5 million (about 4.32327 million yuan). In addition, Merck will pay a double-digit percentage of sales commissions to Abbisko.

146 products of Snibe have obtained IVDR CE certification

Snibe recently announced that 146 products of the company have obtained the certifications issued by the EU notified body -TUV SUD Group, including 72 chemiluminescence reagents and 74 chemiluminescence quality control products. These certifications are valid until December 14 2025.

Up to now, a total of 152 chemiluminescence reagent products and one biochemical reagent product in the new industry have been certified by the International Drug Research and Development Center.

Hipro Biotechoiogy and Swedish POCT diagnostic company Qlife reached a cooperation

Recently, Hipro Biotechnology and Swedish POCT diagnostic company Qlife Holding signed a strategic cooperation agreement, and two sides will comprehensively and deeply cooperate in the field of major health grassroots and home testing, and build a new strategic partnership.

According to the agreement, the two sides will carry out in-depth cooperation in the platform sharing, full agency in China and localization of Egoo Health production.

Wondfo provides technologies to Uganda’s first automated factory

On November 28, Uganda's Microhaem Scientifics (MHS) opened. In response to the Belt and Road Initiative, Wondfu provides a full set of technical support and assistance for the factory construction, helping them to build a quality management system to cope with future reviews by the World Health Organization.

The landing of the factory will provide Africa with high-quality and more affordable diagnostic reagents to benefit more Africas, and jointly improve the level of public health services in Africa.